Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report describes erosive pustular dermatosis of the scalp in a patient undergoing gefitinib treatment for lung cancer, and reviews literature on drug-induced cases of this rare condition.

In this study, a 14-year-old girl developed Malassezia folliculitis and seborrheic dermatitis after starting trametinib, which improved with itraconazole treatment. The research underscores the importance of recognizing trametinib-related skin reactions and suggests managing them with antifungal therapy without necessarily discontinuing the medication.

This report describes a case where hidradenitis suppurativa developed in a patient receiving lithium, adding to the recognized cutaneous side effects like psoriasis, acneiform lesions, and alopecia.

In this prospective study, dabrafenib and trametinib were associated with various skin side effects, including papillomas, hyperkeratosis, and acneiform eruptions in patients with metastatic melanoma.

This paper reviews the diverse skin, nail, and hair changes caused by medications, highlighting hyperpigmentation, alopecia, and nail structural alterations, but reports no new data.

This case report documents a 61-year-old woman treated with erlotinib who experienced the rare side effect of cicatricial alopecia.

In this study, both physician and patient reports revealed that more severe alopecia areata was associated with higher emotional symptoms and greater activity limitations among patients.

In this case series, three patients with advanced non-small cell lung cancer experienced severe skin eruptions and scarring alopecia after treatment with amivantamab, highlighting the critical need for prompt recognition and management of these adverse effects to minimize treatment interruptions.

This study identified potential new adverse drug reaction signals for erlotinib, used in lung and pancreatic cancer treatment, by analyzing a large dataset of case reports, indicating further clinical studies are necessary to confirm these findings.

This review discusses the potential role of Demodex mites in various human skin conditions, including acneiform eruptions and folliculitis, but reports no new research findings.

This article outlines the author's personal strategies for managing dermatological toxicities, such as acneiform rash and dry skin, associated with EGFR inhibitor therapy; it does not present new research findings.

This study found that over half of skin diseases observed in Yemen, particularly in Hajjah, were dermatitis and eczematous disorders, and infections, suggesting the influence of local socioeconomic and environmental factors.

This study found that dermatologic adverse events are common in children taking MEK inhibitors, with selumetinib patients experiencing less severe reactions and a lower risk of dosage adjustments. Age was noted as a factor in the likelihood of specific skin reactions.

The document concludes that various topical medications are effective for skin conditions but often cause skin irritation as a side effect.

This article discusses connubial contact dermatitis, emphasizing its frequent misrecognition and the importance of identifying and eliminating the underlying causes for effective treatment.

This case report highlights a rare instance of erosive pustular dermatosis of the scalp in a patient on afatinib, underlining the importance of early recognition and management of this adverse effect.

In this study, researchers observed that all kidney transplant patients at a Mexico City hospital developed at least one type of skin condition, with infectious dermatoses being the most common. The authors recommend dermatological assessments before transplantation to manage dermatoses, potentially reducing related health risks.

Hair from people with seborrheic dermatitis is thicker scaled, more damaged, and thinner than healthy hair, and atomic force microscopy can help monitor the condition.

This study reports that sorafenib-associated facial acneiform eruption, mimicking chloracne, is a rare cutaneous adverse event which improved upon reducing or discontinuing the drug.

This case report describes a 35-year-old man who developed an atypical DRESS syndrome after taking topiramate for migraine prevention, which resolved with drug withdrawal and symptomatic treatment.

This book reviews the various types of acne and acneiform conditions, as well as their treatment options, with expert insights from multiple fields.

In this study, researchers found that applying topical aprepitant, which blocks substance P receptors, significantly reduced facial dermatitis and hair loss in rats experiencing erlotinib-induced skin side effects, highlighting the neurogenic inflammation's role and the protective effect of ROS inhibition.

A woman was allergic to quinine in her anti-hair loss lotion.

In this study, researchers found that parasitic dermatitis in dogs is predominantly caused by ectoparasites like fleas and mites, with flea allergy dermatitis being particularly prevalent, and noted that diagnosis typically relies on laboratory methods, while treatments involve insectoacaricidal drugs and prevention strategies.

This study found that two sessions of platelet-rich plasma mesotherapy significantly improved symptoms in patients with corticosteroid-induced rosacea-like dermatitis without further treatment.

This report describes a rare case of cyclophosphamide-associated neutrophilic folliculitis, suggesting its inclusion in differential diagnoses for acneiform eruptions.

This review found that JAK/STAT pathway inhibitors, such as tofacitinib and ruxolitinib, led to symptom improvement in all observed atopic dermatitis cases, but responses were mixed for vitiligo and alopecia areata, with a generally mild safety profile reported.

The document concludes that proper diagnosis and treatment of follicular disorders are crucial, with specific treatments for conditions like acne, drug-induced eruptions, and rosacea.

This study observed that isotretinoin was effective in treating acneiform eruptions in HIV-positive women, although side effects like skin xerosis and hair loss were reported.

This review outlines various dermatologic adverse events associated with targeted therapies and immunotherapies, emphasizing the need for collaboration between dermatologists and oncologists to manage these effects effectively; it reports no new clinical findings.